Sorafenib in hepatocellular carcinoma
- PMID: 20852487
- DOI: 10.12968/hmed.2010.71.8.77669
Sorafenib in hepatocellular carcinoma
Abstract
Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
